Galmed Pharma (GLMD) Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study
- S&P 500 hits 2023 closing high as Powell strengthens peak rate bets
- Santa will continue to deliver - Stock Trader's Almanac
- 5 Tesla analysts weigh in as Tesla stock lags after Cybertruck updates
- Shares climb, dollar falls with Fed comments inspiring dovish bets
- Ulta Beauty lifts guidance after Q3 results beat estimates
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6 months in the initiation of its Primary Sclerosing Cholangitis (PSC) Ph 2a Study.
Due to the unexpected events of
Allen Baharaff, CEO and President of Galmed Pharmaceuticals commented " The brutal attack of Hamas on
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA Cautions Public of Safety Issue with Philips' (PHG) DreamStation 2 CPAP Machines
- Palvella Therapeutics and Ligand Pharmaceuticals (LGND) Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN
- Gain Therapeutics (GANX) Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!